Effects of Initiation and Discontinuation of Short Term Zinc Supplementation on Plasma Zinc Concentration

This study has been completed.
Sponsor:
Collaborator:
USDA, Western Human Nutrition Research Center
Information provided by:
University of California, Davis
ClinicalTrials.gov Identifier:
NCT00459485
First received: April 11, 2007
Last updated: February 18, 2010
Last verified: February 2010

April 11, 2007
February 18, 2010
April 2007
December 2007   (final data collection date for primary outcome measure)
Plasma zinc concentration [ Time Frame: 3 weeks ] [ Designated as safety issue: No ]
Plasma zinc concentration
Complete list of historical versions of study NCT00459485 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Effects of Initiation and Discontinuation of Short Term Zinc Supplementation on Plasma Zinc Concentration
Effects of Initiation and Discontinuation of Short Term Zinc Supplementation on the Magnitude and Velocity of Change in Plasma Zinc Concentration

This is a double-blind, randomized controlled trial conducted in men 19-65 years of age who will receive daily zinc supplements (10 or 20 mg zinc/d as zinc sulfate) or placebo for 21 days. Blood samples for plasma zinc and CRP concentrations will be drawn at baseline and days 1, 2, 5, 9, 14, and 21 during supplementation and days 1, 2, 5, 9, and 14 after discontinuation of supplementation.

The study will be a double blind, randomized, placebo controlled trial conducted in men 19-65 years of age. Participants will receive daily zinc or placebo liquid supplements for 21 days. Supplemental zinc will be given as zinc sulfate; the lower dose zinc supplement will contain 10 mg/d elemental zinc, and the higher dose zinc supplement will contain 20 mg/d elemental zinc. The placebo will contain the same excipients expect for zinc sulfate.

Multiple blood draws will be performed throughout the course of the study, to determine the responsiveness of plasma zinc concentrations to zinc supplementation. Two baseline blood draws will occur prior to the start of supplementation (study days -7 and 0). Blood draws will be performed on days 1, 2, 5, 9, 14 and 21 of the 21 day supplementation period. Upon termination of supplementation (day 21), blood draws will be performed on days 1, 2, 5, 9, 14 and 21 post-supplementation (study days 22, 23, 26, 30, 35 and 42).

The major outcomes of interest are the magnitude and velocity of change in plasma zinc concentration. Other outcomes to be assessed are plasma concentrations of the acute phase proteins CRP and AGP, as well as reported morbidity, because of their potential roles as confounding variables. Anthropometric variables will be assessed at baseline.

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Zinc Deficiency
  • Dietary Supplement: zinc sulfate
    20 or 10 mg zinc per day for 3 weeks
    Other Name: Producer: UCD pharmacy
  • Dietary Supplement: Placebo
    Daily placebo for 3 weeks
    Other Name: Producer: UCD pharmacy
  • Experimental: Zinc supplement (20 mg)
    Daily intake of 20 mg supplementary zinc
    Intervention: Dietary Supplement: zinc sulfate
  • Experimental: Zinc supplement (10 mg)
    Daily intake of 10 mg supplementary zinc
    Intervention: Dietary Supplement: zinc sulfate
  • Placebo Comparator: Placebo supplement
    Daily intake of placebo supplement
    Intervention: Dietary Supplement: Placebo
Wessells KR, Jorgensen JM, Hess SY, Woodhouse LR, Peerson JM, Brown KH. Plasma zinc concentration responds rapidly to the initiation and discontinuation of short-term zinc supplementation in healthy men. J Nutr. 2010 Dec;140(12):2128-33. Epub 2010 Oct 13.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
58
December 2007
December 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Generally health men
  • 19-65 years
  • Non-anemic

Exclusion Criteria:

  • Age <19 or >65
  • Hemoglobin <120 g/L
  • Clinical evidence of illness
  • Consumption of mineral supplements
  • Recent blood donation (within 8 weeks)
Male
19 Years to 65 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00459485
200714985, SerumZinc
No
Kenneth Brown, University of California
University of California, Davis
USDA, Western Human Nutrition Research Center
Principal Investigator: Kenneth H Brown, MD University of California, Davis
University of California, Davis
February 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP